Cocaine mechanisms: Enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions

Neuroscience

Volumn 115, Issue 1, 2002, Pages 153-161

  Hall, F S ^a   Li, X F ^a   Sora, I ^a   Xu, F ^a   Caron, M ^b   Lesch, K P ^c   Murphy, D L ^d   Uhl, G R ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Cocaine; Dopamine transporter; Knockout mice; Norepinephrine transporter; Reward; Serotonin transporter

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; COCAINE; DOPAMINE TRANSPORTER; FLUOXETINE; NISOXETINE; NORADRENALIN TRANSPORTER; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ARTICLE; AVERSION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENOTYPE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN TRANSPORT; RECEPTOR BLOCKING; REWARD; WILD TYPE;

ANIMALS; CARRIER PROTEINS; COCAINE; CONDITIONING (PSYCHOLOGY); DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FLUOXETINE; GENE DELETION; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEUROPEPTIDES; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYMPORTERS; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS;

EID: 0037110603     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(02)00379-2     Document Type: Article

References (74)

1. Bardo M.T. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit. Rev. Neurobiol. 12:1998;37-67.
2. Bardo M.T., Bevins R.A. Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology (Berlin). 153:2000;31-43.
3. Beitchman J.H., Adlaf E.M., Douglas L., Atkinson L., Young A., Johnson C.J., Escobar M., Wilson B. Comorbidity of psychiatric and substance use disorders in late adolescence: a cluster analytic approach. Am. J. Drug Alcohol Abuse. 27:2001;421-440.
4. Bengel D., Murphy D.L., Andrews A.M., Wichems C.H., Feltner D., Heils A., Mossner R., Westphal H., Lesch K.P. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ('Ecstasy') in serotonin transporter-deficient mice. Mol. Pharmacol. 53:1998;649-655.
5. Benoit-Marand M., Jaber M., Gonon F. Release and elimination of dopamine in vivo in mice lacking the dopamine transporter: functional consequences [In Process Citation]. Eur. J. Neurosci. 12:2000;2985-2992.
6. Berretta N., Bernardi G., Mercuri N.B. Alpha(1)-adrenoceptor-mediated excitation of substantia nigra pars reticulata neurons. Neuroscience. 98:2000;599-604.
7. Blum, K., Braverman, E.R., Holder, J.M., Lubar, J.F., Monastra, V.J., Miller, D., Lubar, J.O., Chen, T.J., Comings, D.E., 2000. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J. Psychoact. Drugs 32 (Suppl.) i-iv, 1-112.
8. Bonhomme N., De Deurwaerdere P., Le Moal M., Spampinato U. Evidence for 5-HT4 receptor subtype involvement in the enhancement of striatal dopamine release induced by serotonin: a microdialysis study in the halothane-anesthetized rat. Neuropharmacology. 34:1995;269-279.
9. Boulenguez P., Rawlins J.N., Chauveau J., Joseph M.H., Mitchell S.N., Gray J.A. Modulation of dopamine release in the nucleus accumbens by 5-HT1B agonists: involvement of the hippocampo-accumbens pathway. Neuropharmacology. 35:1996;1521-1529.
10. Bowers B.J., Henry M.B., Thielen R.J., McBride W.J. Serotonin 5-HT(2) receptor stimulation of dopamine release in the posterior but not anterior nucleus accumbens of the rat. J. Neurochem. 75:2000;1625-1633.
11. Brebner K., Phelan R., Roberts D.C. Effect of baclofen on cocaine self-administration in rats reinforced under fixed-ratio 1 and progressive-ratio schedules. Psychopharmacology (Berlin). 148:2000;314-321.
12. Carboni E., Spielewoy C., Vacca C., Nosten-Bertrand M., Giros B., Di Chiara G. Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J. Neurosci. 21:2001;RC141.
13. Carroll F.I., Howell L.L., Kuhar M.J. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J. Med. Chem. 42:1999;2721-2736.
14. Carroll F.I., Lewis A.H. Approaches to the treatment of cocaine abuse. Pharm. News. 1:1994;11-17.
15. Chait L.D., Uhlenhuth E.H., Johanson C.E. Reinforcing and subjective effects of several anorectics in normal human volunteers. J. Pharmacol. Exp. Ther. 242:1987;777-783.
16. De Wit H., Wise R.A. Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine. Can. J. Psychol. 31:1977;195-203.
17. DeVries A.C., Taymans S.E., Sundstrom J.M., Pert A. Conditioned release of corticosterone by contextual stimuli associated with cocaine is mediated by corticotropin-releasing factor. Brain Res. 786:1998;39-46.
18. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA. 85:1988;5274-5278.
19. Di Giovanni G., Di Matteo V., Di Mascio M., Esposito E. Preferential modulation of mesolimbic vs. igrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists a combined in vivo electrophysiological and microdialysis study. Synapse. 35:2000;53-61.
20. Di Matteo V., Di Mascio M., Di Giovanni G., Esposito E. Acute administration of amitriptyline and mianserin increases dopamine release in the rat nucleus accumbens: possible involvement of serotonin2C receptors. Psychopharmacology (Berlin). 150:2000;45-51.
21. Dole V.P., Nyswander M.E., Kreek M.J. Narcotic blockade - a medical technique for stopping heroin use by addicts. Trans. Assoc. Am. Physicians. 79:1966;122-136.
22. Ettenberg A., Pettit H.O., Bloom F.E., Koob G.F. Heroin and cocaine intravenous self-administration in rats: mediation by separate neural systems. Psychopharmacology. 78:1982;204-209.
23. Ettenberg A., Raven M.A., Danluck D.A., Necessary B.D. Evidence for opponent-process actions of intravenous cocaine. Pharmacol. Biochem. Behav. 64:1999;507-512.
24. Farrell M., Howes S., Taylor C., Lewis G., Jenkins R., Bebbington P., Jarvis M., Brugha T., Gill B., Meltzer H. Substance misuse and psychiatric comorbidity: an overview of the OPCS National Psychiatric Morbidity Survey. Addict. Behav. 23:1998;909-918.
25. Fletcher P.J., Korth K.M. Activation of 5-HT1B receptors in the nucleus accumbens reduces amphetamine-induced enhancement of responding for conditioned reward. Psychopharmacology (Berlin). 142:1999;165-174.
26. Fletcher P.J., Tampakeras M., Yeomans J.S. Median raphe injections of 8-OH-DPAT lower frequency thresholds for lateral hypothalamic self-stimulation. Pharmacol. Biochem. Behav. 52:1995;65-71.
27. Frank R.A., Zubrycki E. Chronic imipramine does not block cocaine-induced increases in brain stimulation reward. Pharmacol. Biochem. Behav. 33:1989;725-727.
28. Gainetdinov R.R., Jones S.R., Caron M.G. Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol. Psychiatry. 46:1999;303-311.
29. Gawin F.H. Cocaine addiction: psychology and neurophysiology. Science. 251:1991;1580-1586.
30. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
31. Grabowski J., Roache J.D., Schmitz J.M., Rhoades H., Creson D., Korszun A. Replacement medication for cocaine dependence: methylphenidate. J. Clin. Psychopharmacol. 17:1997;485-488.
32. Hall F.S., Sora I., Uhl G.R. Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology (Berlin). 154:2001;43-49.
33. Harrison A.A., Parsons L.H., Koob G.F., Markou A. RU 24969, a 5-HT1A/1B agonist, elevates brain stimulation reward thresholds: an effect reversed by GR 127935, a 5-HT1B/1D antagonist. Psychopharmacology (Berlin). 141:1999;242-250.
34. Jones S.R., Gainetdinov R.R., Jaber M., Giros B., Wightman R.M., Caron M.G. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. USA. 95:1998;4029-4034.
35. Kreek M.J. Opiate and cocaine addictions: challenge for pharmacotherapies. Pharmacol. Biochem. Behav. 57:1997;551-569.
36. Kuhar M.J., Ritz M.C., Boja J.W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 14:1991;299-302.
37. Kushner S.A., Dewey S.L., Kornetsky C. The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. J. Pharmacol. Exp. Ther. 290:1999;797-802.
38. Lavori P.W., Bloch D.A., Bridge P.T., Leiderman D.B., LoCastro J.S., Somoza E. Plans, designs, and analyses for clinical trials of anti-cocaine medications: where we are today, IDA/VA/SU Working Group on Design and Analysis. J. Clin. Psychopharmacol. 19:1999;246-256.
39. Lejeune F., Millan M.J. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100, 635-reversible actions of the highly selective ligands, flesinoxan and S 15535. Synapse. 30:1998;172-180.
40. Li Q., Wichems C., Heils A., Lesch K.P., Murphy D.L. Reduction in the density and expression, but not G-protein coupling, of serotonin receptors (5-HT1A) in 5-HT transporter knock-out mice: gender and brain region differences. J. Neurosci. 20:2000;7888-7895.
41. Li Q., Wichems C., Heils A., Van De Kar L.D., Lesch K.P., Murphy D.L. Reduction of 5-hydroxytryptamine (5-HT)(1A)-mediated temperature and neuroendocrine responses and 5-HT(1A) binding sites in 5-HT transporter knockout mice. J. Pharmacol. Exp. Ther. 291:1999;999-1007.
42. Lobl, J.K., Carbone, L.D., 1992. Emergency management of cocaine intoxication. Counteracting the effects of today's 'favorite drug'. Postgrad. Med. 91, 161-162, 165-166.
43. Logan J., Volkow N.D., Fowler J.S., Wang G.J., Fischman M.W., Foltin R.W., Abumrad N.N., Vitkun S., Gatley S.J., Pappas N., Hitzemann R., Shea C.E. Concentration and occupancy of dopamine transporters in cocaine abusers with [11C]cocaine and PET. Synapse. 27:1997;347-356.
44. Miliaressis E. Serotonergic basis of reward in median raphe of the rat. Pharmacol. Biochem. Behav. 7:1977;177-180.
45. Pettit H.O., Ettenberg A., Bloom F.E., Koob G.F. Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology. 84:1984;167-173.
46. Poschel B.P. Proceedings: Role of norepinephrine, dopamine, and serotonin in intracranial reward. Psychopharmacol. Bull. 10:1974;46-47.
47. Redgrave P. Modulation of intracranial self-stimulation behaviour by local perfusions of dopamine, noradrenaline and serotonin within the caudate nucleus and nucleus accumbens. Brain Res. 155:1978;277-295.
48. Roberts D.C., Andrews M.M., Vickers G.J. Baclofen attenuates the reinforcing effects of cocaine in rats. Neuropsychopharmacology. 15:1996;417-423.
49. Roberts D.C., Corcoran M.E., Fibiger H.C. On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. Pharmacol. Biochem. Behav. 6:1977;615-620.
50. Robinson M.B., Anegawa N.J., Gorry E., Qureshi I.A., Coyle J.T., Lucki I., Batshaw M.L. Brain serotonin2 and serotonin1A receptors are altered in the congenitally hyperammonemic sparse fur mouse. J. Neurochem. 58:1992;1016-1022.
51. Rocha B.A., Fumagalli F., Gainetdinov R.R., Jones S.R., Ator R., Giros B., Miller G.W., Caron M.G. Cocaine self-administration in dopamine-transporter knockout mice [see comments] [published erratum appears in Nature Neurosci. 1 (1998) 330]. Nature Neurosci. 1:1998;132-137.
52. Rocha B.A., Scearce-Levie K., Lucas J.J., Hiroi N., Castanon N., Crabbe J.C., Nestler E.J., Hen R. Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. Nature. 393:1998;175-178.
53. Rothman R.B., Glowa J.R. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909. Mol. Neurobiol. 11:1995;1-19.
54. Satel S.L., Southwick S.M., Gawin F.H. Clinical features of cocaine induced paranoia. NIDA Res. Monogr. 105:1991;371.
55. Shi W.X., Pun C.L., Zhang X.X., Jones M.D., Bunney B.S. Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors. J. Neurosci. 20:2000;3504-3511.
56. Sora I., Elmer G., Funada M., Pieper J., Li X.F., Hall F.S., Uhl G.R. Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology. 25:2001;41-54.
57. Sora I., Hall F.S., Andrews A.M., Itokawa M., Li X.F., Wei H.B., Wichems C., Lesch K.P., Murphy D.L., Uhl G.R. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc. Natl. Acad. Sci. USA. 98:2001;5300-5305.
58. Sora I., Takahashi N., Funada M., Ujike H., Revay R.S., Donovan D.M., Miner L.L., Uhl G.R. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl. Acad. Sci. USA. 94:1997;1544-1549.
59. Sora I., Wichems C., Takahashi N., Li X.F., Zeng Z., Revay R., Lesch K.P., Murphy D.L., Uhl G.R. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl. Acad. Sci. USA. 95:1998;7699-7704.
60. Spealman R.D., Madras B.K., Bergman J. Effects of cocaine and related drugs in nonhuman primates. II. Stimulant effects on schedule-controlled behavior. J. Pharmacol. Exp. Ther. 251:1989;142-149.
61. Takahashi N., Miner L.L., Sora I., Ujike H., Revay R.S., Kostic V., Jackson-Lewis V., Przedborski S., Uhl G.R. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. USA. 94:1997;9938-9943.
62. Tella S.R. Effects of monoamine reuptake inhibitors on cocaine self-administration in rats. Pharmacol. Biochem. Behav. 51:1995;687-692.
63. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog. Neurobiol. 56:1998;613-672.
64. Volkow N.D., Wang G.J., Fischman M.W., Foltin R.W., Fowler J.S., Abumrad N.N., Vitkun S., Logan J., Gatley S.J., Pappas N., Hitzemann R., Shea C.E. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 386:1997;827-830.
65. West A.R., Galloway M.P. Regulation of serotonin-facilitated dopamine release in vivo: the role of protein kinase A activating transduction mechanisms. Synapse. 23:1996;20-27.
66. Wilson M.C., Schuster C.R. Aminergic influences on intravenous cocaine self-administration by Rhesus monkeys. Pharmacol. Biochem. Behav. 2:1974;563-571.
67. Wilson M.C., Schuster C.R. Mazindol self-administration in the rhesus monkey. Pharmacol. Biochem. Behav. 4:1976;207-210.
68. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol. Rev. 94:1987;469-492.
69. Woolverton W.L., Johnson K.M. Neurobiology of cocaine abuse. Trends Pharmacol. Sci. 13:1992;193-200.
70. Xu F., Gainetdinov R.R., Wetsel W.C., Jones S.R., Bohn L.M., Miller G.W., Wang Y.M., Caron M.G. Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nature Neurosci. 3:2000;465-471.
71. Yadid G., Pacak K., Kopin I.J., Goldstein D.S. Endogenous serotonin stimulates striatal dopamine release in conscious rats. J. Pharmacol. Exp. Ther. 270:1994;1158-1165.
72. Yanagita T., Katoh S., Wakasa Y., Oinuma N. Dependence potential of buprenorphine studied in rhesus monkeys. NIDA Res. Monogr. 41:1982;208-214.
73. Yokel R.A., Wise R.A. Increased lever pressing for amphetamine after pimozide in rats: implications for a dopamine theory of reward. Science. 187:1975;547-549.
74. Yokel R.A., Wise R.A. Attenuation of intravenous amphetamine reinforcement by central dopamine blockade in rats. Psychopharmacology (Berlin). 48:1976;311-318.